Abstract
In addition to progesterone, which can be synthesized and secreted by the ovary, placenta, adrenal and many other organs, there are different classes of progestogens, which also known as progestins which are synthetic. Each progestogen has a particular pattern of partial effects leading to different partial effects at the tissue level based on structural differences derived from different basic compounds. This partial effect pattern affects clinical use and should be taken into consideration for clinical purposes. Based upon this pattern of partial effects, each progestogen may result in different tissue effects and different effects on carbohydrate and lipid metabolism. It has been recently demonstrated that progestogens combined with estrogens also have different effect on the hemostatic system leading to differences in venous thromboembolic risk, depending on the type of the progestogens used.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Williams CL, Stancel GM. The pharmacological basis of therapeutics. In: Goodman L, Gilman A, editors. . Elmsford: Pergamon Press; 2011. p. 1411–40.
Morville R, Dray F, Regnier J, Barrat J. The bioavailability of natural progesterone given by month. Measurements of steroid concentration in plasma, endometrium and breast tissue. J Gynecol Obstet Biol Reprod (Paris). 1982;11:355–63.
Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestogens. Maturitas. 2003;46(Suppl.1):S7–S16.
Stanczyk FZ, Hapgood JP, Winter SH, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions and clinical effects. Endocr Rev. 2013;34:171–208.
Kuhl H. Pharmacology of progestogens. J Reproduktionsmed Endokrinol. 2011;8(Suppl.1):157–76.
Reesink EH, Schöler HFL, Westerhof P, et al. A new class of hormonally active steroids. Nature. 1960;186:168–9.
Wiechart R. Analogue based drug discovery. In: Fisher J, Ganellin CR, editors. IUPAC. Weinheim: Wiley VCH Verlag GmbH & Co.; 2006. p. 395–400.
Schindler AE. Progestogens and thromboembolic risk. In: Berga S, Fauser WJM, Genazzani AR, editors. Frontiers in gynecological endocrinology. New York: Springer; 2015. p. 68–75.
Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effect of a novel, estradiol based contraceptive. Drugs. 2011;11:159–70.
Junge W, Mellinger U, Parke S, Serrani M. Metabolic and hemostatic effects of estradiol valerate/dienogest, novel contraceptive. Clin. Drug Invest. 2011;211(31):573–84.
Van Vliet HA, Frolich M, Christella M, Thomassen LG, Doggen CJ, Rosendaal FR, Rosing J, Helmerhorst FM. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod. 2005;20:563–8.
Mueck A, Neulen J, Thaler CHR, Birkhäuser M, Braendle W, Kiesel L, Kuhl H. Kontrazeption bei Problemfällen. Therapeut. Umschau. 2009;66:117–28.
Lidegard O, Milson I, Geiersonn RD, Skjeldestad FE. Hormonal contraception and venous thrombosis. Acta Obstet Gynecol Scand. 2012;91:769–78.
Parkin L, Scharples K, Hernandez LK. Risk of venous thromboembolism in users of oral contraceptives containing drospirenonem or Levonorgestrel: Nested case-control study based on UK Gneral practice research DATA-base. BMJ. 2011;342:d2139.
Jick SS, Hernandez PK. Risk of non-fetal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case control study using United States claims Data. BMJ. 2011;742:d2151.
Culwell KR, Cartis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a system review. Contraception. 2009;80:337–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schindler, A.E. (2021). Pharmacology of Progestogens. In: Carp, H.J. (eds) Progestogens in Obstetrics and Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-030-52508-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-52508-8_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-52507-1
Online ISBN: 978-3-030-52508-8
eBook Packages: MedicineMedicine (R0)